ACE2 decoy Fc-fusions and bispecific killer engagers require Fc engagement for in vivo efficacy against SARS-CoV-2
The Journal of Immunology · 04.08.2026 · 215 (8)
DOI: 10.1093/jimmun/vkag235 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 23.08.2026. Verfasst von Jenna K Dick und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Disease and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, MN, United States. Hauptthemen laut MEDLINE: Angiotensin-Converting Enzyme 2, SARS-CoV-2, Antibodies, Bispecific, COVID-19. Die Arbeit nennt 96 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NIH HHS, University of Minnesota.
Abstract (Originalsprache)
SARS-CoV-2 has continued to evolve over time, necessitating the adaptation of vaccines to maintain efficacy. Monoclonal antibodies (mAbs) against SARS-CoV-2 were a key line of defense for unvaccinated or immunocompromised individuals. However, these mAbs are now ineffective against current SARS-CoV-2 variants. Here, we tested 3 aspects of αSARS-CoV-2 therapeutics. First, we tested whether Fc engagement is necessary for in vivo clearance of SARS-CoV-2. Second, we tested bispecific killer engagers (BiKEs) that simultaneously engage SARS-CoV-2 and a specific Fc receptor. Benefits of these engagers include the ease of manufacturing, stability, more cell-specific targeting, and high affinity binding to Fc receptors. Using both mAbs and BiKEs, we found that both neutralization and Fc receptor engagement were necessary for effective SARS-CoV-2 clearance. Third, due to ACE2 being necessary for viral entry, ACE2 will maintain binding to SARS-CoV-2 despite viral evolution. Therefore, we used an ACE2 decoy Fc-fusion or BiKE, instead of an αSARS-CoV-2 antibody sequence, as a potential therapeutic that would withstand viral evolution. We found that the ACE2 decoy approach also required Fc receptor engagement and, unlike traditional neutralizing antibodies against specific variants, enabled the clearance of two distinct SARS-CoV-2 variants. These data show the importance of Fc engagement for mAbs, the utility of BiKEs as therapies for infectious disease, and the in vivo effectiveness of the ACE2 decoy approach. With further studies, we predict that combining neutralization, the cellular response, and this ACE2 decoy approach will benefit individuals with ineffective antibody levels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Disease and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, MN, United States.
- Center for Immunology, University of Minnesota, Minneapolis, MN, United States.
- Department of Veterinary Population Medicine, University of Minnesota, St. Paul, MN, United States.
- Department of Pharmacology, University of Minnesota, Minneapolis, MN, United States.
- Antibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
- Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands.
ORCID-Profile: Mark S Cragg
Förderung
- NIA NIH HHS
- NIH HHS
- University of Minnesota
- Department of Veterinary Medicine, and the Clinical and Translational Science Institute
- Department of Medicine, Department of Pharmacology
- National Institutes of Health
Zitieren
APA
Dick, J. K., Krishna, V. D., Hicks, D., Sangala, J. A., Oldham, R. J., Zandstra, B. T., Baehr, C., Verbeek, J. S., Cragg, M. S., Pravetoni, M., Cheeran, M. C., & Hart, G. T. (2026). ACE2 decoy Fc-fusions and bispecific killer engagers require Fc engagement for in vivo efficacy against SARS-CoV-2. The Journal of Immunology, 215(8). https://doi.org/10.1093/jimmun/vkag235
Vancouver
Dick JK, Krishna VD, Hicks D, Sangala JA, Oldham RJ, Zandstra BT, et al. ACE2 decoy Fc-fusions and bispecific killer engagers require Fc engagement for in vivo efficacy against SARS-CoV-2. The Journal of Immunology. 2026;215(8). doi:10.1093/jimmun/vkag235
BibTeX
@article{Dick2026,
author = {Dick, Jenna K and Krishna, Venkatramana D and Hicks, Dustin and Sangala, Jules A and Oldham, Robert J and Zandstra, Benjamin T and Baehr, Carly and Verbeek, J Sjef and Cragg, Mark S and Pravetoni, Marco and Cheeran, Maxim C-J and Hart, Geoffrey T},
title = {ACE2 decoy Fc-fusions and bispecific killer engagers require Fc engagement for in vivo efficacy against SARS-CoV-2},
journal = {The Journal of Immunology},
year = {2026},
volume = {215},
number = {8},
doi = {10.1093/jimmun/vkag235}
}
EUVIMED